Research programme: Tau protein modulators - Abbvie/BioMed X
Latest Information Update: 06 Jun 2015
At a glance
- Originator AbbVie; BioMed X
- Mechanism of Action Tau protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Alzheimer's disease
Most Recent Events
- 30 Mar 2015 Early research in Alzheimer's disease in Germany (unspecified route)